These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15883614)

  • 1. Inflammatory biomarkers and statins.
    Blanco-Colio LM; Tuñón J; Martín-Ventura JL; Egido J
    Drugs Today (Barc); 2005 Mar; 41(3):171-7. PubMed ID: 15883614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory biomarkers and statins.
    Blanco-Colio LM; Tuñón J; Martín-Ventura JL; Egido J
    Timely Top Med Cardiovasc Dis; 2005 Jun; 9():E16. PubMed ID: 15944749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and inflammatory markers.
    Case CC; Ballantyne CM
    Curr Atheroscler Rep; 2002 Jan; 4(1):42-7. PubMed ID: 11772421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of inflammation and their clinical significance.
    Ballantyne CM; Nambi V
    Atheroscler Suppl; 2005 May; 6(2):21-9. PubMed ID: 15823493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins and other agents for vascular inflammation.
    Owens CD
    J Vasc Surg; 2012 Dec; 56(6):1799-806. PubMed ID: 23017371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.
    Diamantis E; Kyriakos G; Quiles-Sanchez LV; Farmaki P; Troupis T
    Curr Cardiol Rev; 2017; 13(3):209-216. PubMed ID: 28462692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM
    Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance.
    Biasucci LM; Biasillo G; Stefanelli A
    Clin Chem Lab Med; 2010 Dec; 48(12):1685-91. PubMed ID: 20868311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors].
    Rosendo AB; Dal-Pizzol F; Fiegenbaum M; Almeida Sd
    Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):520-5. PubMed ID: 17684611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-Hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes.
    Blum A; Simsolo C; Hasin Y
    Atherosclerosis; 2004 Jul; 175(1):1-5. PubMed ID: 15186940
    [No Abstract]   [Full Text] [Related]  

  • 15. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward immunomodulatory and anti-inflammatory properties of statins.
    Arnaud C; Braunersreuther V; Mach F
    Trends Cardiovasc Med; 2005 Aug; 15(6):202-6. PubMed ID: 16182129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity.
    Puttananjaiah MK; Dhale MA; Gaonkar V; Keni S
    Appl Biochem Biotechnol; 2011 Jan; 163(2):215-22. PubMed ID: 20640529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
    Di Napoli M; Schwaninger M; Cappelli R; Ceccarelli E; Di Gianfilippo G; Donati C; Emsley HC; Forconi S; Hopkins SJ; Masotti L; Muir KW; Paciucci A; Papa F; Roncacci S; Sander D; Sander K; Smith CJ; Stefanini A; Weber D
    Stroke; 2005 Jun; 36(6):1316-29. PubMed ID: 15879341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.